Adverse effect · Adipotide

How common is kidney toxicity with Adipotide?

D
Grade D — no human evidencePreclinical only · effect size: not measurable · adverse
Short answerNo human evidence. As of 10 September 2026, only preclinical only exist for Adipotide for kidney toxicity. At effective doses, monkeys of three species showed predictable, dose-dependent changes in proximal tubule function that reversed when treatment stopped. The mechanism — the homing sequence also binds in the kidney — is the reason development stalled and the reason human use without monitoring is reckless.

What the studies show

At effective doses, monkeys of three species showed predictable, dose-dependent changes in proximal tubule function that reversed when treatment stopped. The mechanism — the homing sequence also binds in the kidney — is the reason development stalled and the reason human use without monitoring is reckless.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

  1. 1

In context

Adipotide is a two-part synthetic peptide: a homing sequence that binds a protein on the blood vessels of white fat, joined to a fragment that triggers cell death. Cut off the blood supply and the fat tissue shrinks. In obese monkeys it produced rapid weight loss and better insulin sensitivity — and dose-dependent, reversible kidney damage. A human phase 1 trial in prostate cancer was registered in 2010 and no result was ever published. It is sold online as a fat-loss peptide on the strength of the monkey study. It is not approved anywhere and is prohibited in sport.

Adipotide is not approved; investigational (stalled). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Adipotide proven to cause kidney toxicity?
No. There is no human evidence for it (Preclinical only); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
At effective doses, monkeys of three species showed predictable, dose-dependent changes in proximal tubule function that reversed when treatment stopped. The mechanism — the homing sequence also binds in the kidney — is the reason development stalled and the reason human use without monitoring is reckless.
Is Adipotide approved for this?
No. Adipotide is not approved; investigational (stalled); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Adipotide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →